• KOL
    • Dialysis Patients
    • Sagar Uday Nigwekar
    • Sagar Uday Nigwekar: Influence Statistics

      Sagar Uday Nigwekar

      Sagar Uday Nigwekar

      Show email address

      Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA | Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA. | Division of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Sagar Uday Nigwekar:Expert Impact

      Concepts for whichSagar Uday Nigwekarhas direct influence:Dialysis patients,Sickle cell trait,Patients calciphylaxis,Chronic kidney disease,Kidney disease,Hip fracture,Kidney transplant recipients,Aldosterone antagonists.

      Sagar Uday Nigwekar:KOL impact

      Concepts related to the work of other authors for whichfor which Sagar Uday Nigwekar has influence:Chronic kidney disease,Acute kidney injury,Vascular calcification,Cardiac surgery,Dialysis patients,Sodium thiosulfate,Renal function.

      KOL Resume for Sagar Uday Nigwekar

      Year
      2022

      Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA

      2021

      Harvard Medical School, Boston, MA, USA

      Department of Nephrology, Massachusetts General Hospital, Boston, Massachusetts.

      2020

      Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

      Department of Nephrology, Massachusetts General Hospital, Boston, Massachusetts

      2019

      Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA 02114, USA.

      Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

      2018

      Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA

      Harvard Medical School, Boston, Massachusetts

      2017

      Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

      Department of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA

      Harvard Medical School, Boston, Massachusetts; and.

      2016

      Department of Internal Medicine/Nephrology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA

      Massachusetts General Hospital Division of Nephrology Boston Massachusetts

      2015

      Division of Nephrology, Massachusetts General Hospital, Boston, MA

      Massachusetts General Hospital, Department of Medicine, 55 Fruit Street, Boston, Massachusetts 02114, United States.

      2014

      Massachusetts General Hospital, Boston, MA, USA

      2013

      Division of Nephrology, Massachusetts General Hospital, Bulfinch 127, Boston, MA 02114, USA

      Scholars in Clinical Science Program, Harvard Medical School, Boston, Massachusetts;

      2012

      Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

      2011

      Division of Nephrology, Massachusetts General Hospital, Boston, MA and Scholars in Clinical Science Program, Harvard Medical School, Boston, MA

      University of Rochester School of Medicine, Rochester General Hospital, Rochester, New York;

      2010

      Clinical Epidemiology Research Center, Veterans Affairs Medical Center, West Haven, Conn., Department of Medicine, Yale University School of Medicine, New Haven, Conn., and, Department of Medicine, University of Rochester School of Medicine, Rochester, N.Y., USA;, Division of Nephrology and, Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ont., and, Institute for Clinical Evaluative Sciences, Toronto, Ont., Canada;, Department of Anesthesiology, Yale University School of Medicine, New Haven, Conn., USA

      2009

      Internal Medicine, Rochester General Hospital, Rochester, USA

      *Department of Nephrology and Hypertension, Glickman Institute of Urological and Kidney Diseases, Cleveland Clinic, Cleveland, Ohio; ‡Department of Medicine, Rochester General Hospital, Rochester, New York; §Division of Nephrology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio; ‖Department of Pharmacology and Clinical Epidemiology, Mario Negri Sud Consortium, S. Maria Imbaro, Italy; ¶Diaverum Corporate Medical Scientific Office, Lund Sweden; †Cochrane Renal Group, Sydney, Australia; **School of Public Health, University of Sydney, Sydney, Australia

      Department of Medicine, Rochester General Hospital, Rochester, NY; University of Rochester School of Medicine and Dentistry, Rochester, NY

      2008

      Departments of *Internal Medicine and ‡Nephrology, Rochester General Hospital and University of Rochester School of Medicine, Rochester, New York; and †Renal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

      Department of Internal Medicine, Rochester General Hospital and University of Rochester, Rochester, New York

      2007

      Rochester General Hospital, Rochester, NY

      2006

      Internal Medicine, Rochester General Hospital, Rochester, NY 14621, USA.

      2004

      Department of Internal Medicine, Rochester General Hospital, Rochester, NY 14621, USA.

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Sagar Uday Nigwekar is among the top experts in the world.
      Concept World rank
      apixaban dialysis #1
      ckd histologic #1
      micronutrient iron deficiencies #1
      calciphylaxis calcium #1
      hospitalized patients calciphylaxis #1
      efficacy calcification scores #1
      superficial calcium deposits #1
      calciphylaxis primary #1
      ckd theknee #1
      faster sickle #1
      patients sodium thiosulfate #1
      vascular calcification calciphylaxis #1
      ckd olfactory #1
      prognosis nonuremic #1
      calciphylaxis renal #1
      thiosulfate therapy #1
      calciphylaxis renal disease #1
      adequate specimens calciphylaxis #1
      trials ascertain #1
      digestive anatomy abnormalities #1
      ckd vulnerable population #1
      26990 patients #1
      calciphylaxis rare disorder #1
      calciphylaxis vascular #1
      normal hemoglobin phenotype #1
      literature calciphylaxis #1
      calciphylaxis review #1
      27549 #1
      investigational studies patients #1
      incident sustained #1
      bmd sts #1
      patients calciphylaxis #1
      nonuremic systematic #1
      sna 110 meq #1
      treatment calciphylaxis #1
      sts treatment patients #1
      110 meq sna #1
      calciphylaxis methods #1
      dialysis unanswered questions #1
      therapeutic options calciphylaxis #1
      clinical investigational studies #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Sagar Uday Nigwekar

      KOL-Index: 20607

      BACKGROUND: People with chronic kidney disease (CKD) have higher risks of cardiovascular disease compared to the general population. Specifically, cardiovascular deaths account most deaths in kidney transplant recipients. Statins are a potentially beneficial intervention for kidney transplant patients given their established benefits in patients at risk of cardiovascular disease in the general population. This is an update of a review first published in 2009.

      OBJECTIVES: We aimed to ...

      Known for Kidney Transplant Recipients | Cardiovascular Events | Coa Reductase | Placebo Treatment | Statins Mortality
      KOL-Index: 18754

      BACKGROUND: People with advanced kidney disease treated with dialysis experience mortality rates from cardiovascular disease that are substantially higher than for the general population. Studies that have assessed the benefits of statins (HMG CoA reductase inhibitors) report conflicting conclusions for people on dialysis and existing meta-analyses have not had sufficient power to determine whether the effects of statins vary with severity of kidney disease. Recently, additional data for ...

      Known for Dialysis Patients | 95 Statins | Reductase Inhibitors | Cardiovascular Events | Treatment Effects
      KOL-Index: 15447

      BACKGROUND: Treatment with angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) is increasingly used to reduce proteinuria and retard the progression of chronic kidney disease (CKD). But some patients do not attain complete resolution of proteinuria and might have higher aldosterone levels within few months of treatment. The addition of aldosterone antagonists may be beneficial to these patients for reduction of progression of renal damage.

      OBJECTIVES: ...

      Known for Aldosterone Antagonists | Acei Arb | Chronic Kidney | Patients Ckd | And Or
      KOL-Index: 12763

      BACKGROUND: Cardiovascular disease accounts for more than half the number of deaths among dialysis patients. The role of HMG CoA reductase inhibitors (statins) in the treatment of dyslipidaemia in dialysis patients is unclear and their safety has not been established.

      OBJECTIVES: To assess the benefits and harms of statins in peritoneal dialysis (PD) and haemodialysis patients (HD).

      SEARCH STRATEGY: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled trials (CENTRAL, ...

      Known for Dialysis Patients | Reductase Inhibitors | 95 Cardiovascular Mortality | Placebo Treatment | Hmg Coa
      KOL-Index: 12440

      BACKGROUND: Cardiovascular deaths account for the majority of deaths in kidney transplant recipients and dyslipidaemia contributes significantly to their cardiovascular disease. Statins are widely used in kidney transplant patients given their established benefits in the general population, however evidence favouring their use is lacking.

      OBJECTIVES: To assess the benefits and harms of statin therapy on mortality and renal outcomes in kidney transplant recipients.

      SEARCH STRATEGY: We ...

      Known for Kidney Transplant Recipients | Reductase Inhibitors | Statins Placebo | Cardiovascular Mortality | Statin Therapy
      KOL-Index: 11898

      OBJECTIVE: To systematically review the effect of folic acid based homocysteine lowering on cardiovascular outcomes in people with kidney disease.

      DESIGN: Systematic review and meta-analysis.

      DATA SOURCES: Medline, Embase, the Cochrane Library, and ClinicalTrials.gov to June 2011.

      STUDY SELECTION: Randomised trials in people with non-dialysis dependent chronic kidney disease or end stage kidney disease or with a functioning kidney transplant reporting at least 100 patient years of ...

      Known for Cardiovascular Events | Kidney Disease | Folic Acid | Homocysteine Lowering | Myocardial Infarction
      KOL-Index: 11653

      BACKGROUND AND OBJECTIVES: Addition of aldosterone antagonists (AA) might provide renal benefits to proteinuric chronic kidney disease (CKD) patients over and above the inhibition of renin-angiotensin system blockers (RAS). We evaluated the benefits and harms of adding selective and nonselective AA in CKD patients already on RAS.

      DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: MEDLINE, EMBASE, and Renal Health Library were searched for relevant randomized clinical trials in adult CKD ...

      Known for Aldosterone Antagonists | Chronic Kidney | Ckd Patients | Risk Hyperkalemia | Acei Arb
      KOL-Index: 11352

      Chronic kidney disease-mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was ...

      Known for Chronic Kidney | Bone Disorder | Clinical Practice Guideline | Treatment Ckdmbd | Disease Ckd
      KOL-Index: 11226

      Aortic calcification is an important independent predictor of future cardiovascular events. We performed a genome-wide association meta-analysis to determine SNPs associated with the extent of abdominal aortic calcification (n = 9,417) or descending thoracic aortic calcification (n = 8,422). Two genetic loci, HDAC9 and RAP1GAP, were associated with abdominal aortic calcification at a genome-wide level (P < 5.0 × 10−8). No SNPs were associated with thoracic aortic calcification at the ...

      Known for Aortic Calcification | Smooth Muscle | Abdominal Aorta | Genome Wide | Genetic Loci
      KOL-Index: 10733

      BACKGROUND: Sickle cell trait and sickle cell disease are thought to be independent risk factors for CKD, but the trajectory and predictors of kidney function decline in patients with these phenotypes are not well understood.

      METHODS: Our multicenter, observational study used registry data (collected January 2005 through June 2018) and included adult black patients with sickle cell trait or disease (exposures) or normal hemoglobin phenotype (reference) status (ascertained by ...

      Known for Sickle Cell Trait | Cell Disease | Black Patients | Kidney Function | Registry Data
      KOL-Index: 10400

      CONTEXT: It is uncertain which osteoporosis therapy is more effective: bisphosphonates or denosumab.

      OBJECTIVE: To determine whether denosumab therapy increases bone mineral density (BMD) and reduces fracture risk more so than bisphosphonates in patients with low BMD or osteoporosis.

      METHODS: The PubMed, Embase, and the Cochrane Library databases were searched through November 2018 for head-to-head, randomized, controlled trials comparing denosumab and bisphosphonates among adult ...

      Known for Randomized Controlled | Denosumab Bmd | Patients Osteoporosis | 12 Months | Lumbar Spine
      KOL-Index: 9743

      BACKGROUND AND OBJECTIVES: Severe hyponatremia (<120 mEq/L) in hospitalized patients has a high mortality rate. We hypothesized that underlying diseases causing hyponatremia attribute to mortality rather than hyponatremia itself.

      DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The relationship between mortality and serum sodium (sNa) was examined in 45,693 patients admitted to a single community teaching hospital between January 1996 and December 2007. We conducted a comprehensive ...

      Known for Patients Hyponatremia | Serum Sodium | 120 Meq | Mortality Rate | Underlying Diseases
      KOL-Index: 9670

      BACKGROUND: Cardiovascular disease accounts for more than half the number of deaths among dialysis patients. The role of HMG CoA reductase inhibitors (statins) in the treatment of dyslipidaemia in dialysis patients is unclear and their safety has not been established.

      OBJECTIVES: To assess the benefits and harms of statins in peritoneal dialysis (PD) and haemodialysis patients (HD).

      SEARCH STRATEGY: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled trials (CENTRAL, ...

      Known for Dialysis Patients | Statins Placebo | Reductase Inhibitors | Cardiovascular Disease | Humans Hydroxymethylglutaryl
      KOL-Index: 8965

      BACKGROUND: Late referral to nephrologists is common and associated with increased morbidity and mortality. We aimed to analyze the prevalence rates, predictors and consequences of late referral to nephrologists by primary care physicians for chronic kidney disease (CKD) care.

      METHODS: A retrospective analysis of 204 patients started on dialysis for CKD in two community hospitals between March 2003 and March 2005 was conducted. Relevant clinical and laboratory data were obtained from the ...

      Known for Late Referral | Kidney Disease | Retrospective Analysis | Primary Physicians | Patients Ckd
      KOL-Index: 8924

      BACKGROUND: Insulin resistance is associated with increased sympathetic and reduced parasympathetic activity. Resting heart rate reflects autonomic activity. Therefore, we examined the associations of resting heart rate with insulin resistance, cardiovascular events and mortality in the moderate chronic kidney disease (CKD) population.

      METHODS: Four hundred and sixty participants with MDRD GFR <60 ml/min/1.73 m(2) in the limited access Atherosclerosis Risk in Communities (ARIC) study ...

      Known for Heart Rate | Insulin Resistance | Chronic Kidney | Metabolic Syndrome | Cardiovascular Events

      Key People For Dialysis Patients

      Top KOLs in the world
      #1
      Friedrich K Port
      practice patterns study united states dialysis outcomes
      #2
      Glenn Matthew Chertow
      chronic kidney disease acute kidney injury united states
      #3
      Andrew S Levey
      kidney disease serum creatinine glomerular filtration rate
      #4
      Kamyar KALANTAR‐ZADEH
      kidney disease dialysis patients united states
      #5
      Robert N Foley
      united states dialysis patients cardiovascular disease
      #6
      Patrick S Parfrey
      colorectal cancer dialysis patients cardiovascular disease

      Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA | Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA. | Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Harvard Me

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.